TerminatedNCT03310593
Cannabidiol as an Adjunctive Treatment for Depression in bipolarity
Medication studyAges 18–70Brazil
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- Porto AlegreSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 1, 2017
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 36
- Sponsor
- Hospital de Clinicas de Porto Alegre
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Brazil
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT03310593
- Official title
Show the full official title
A Double-blind, Randomized, Placebo-controlled Clinical Trial of Adjunctive Cannabidiol for Bipolar Depression
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Porto Alegre
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Hospital de Clinicas de Porto Alegre, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol and Placebo.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolarity type I
Lacosamide or placebo added to usual care for treatment-resistant depression in type I or II bipolarity